- BioNTech completed the acquisition of InstaDeep, announced on January 10, 2023.
- The acquisition cost approximately €500 million in cash, shares, and milestone payments.
- InstaDeep will operate as a UK-based global subsidiary of BioNTech.
- The acquisition adds 290 professionals to BioNTech’s workforce.
Acquisition Completion
BioNTech SE has completed the acquisition of InstaDeep Ltd., a global technology company specializing in artificial intelligence (AI) and machine learning (ML). The acquisition, initially announced on January 10, 2023, follows a history of collaboration between the two companies since 2019, including BioNTech’s initial equity investment during InstaDeep’s Series B financing round in January 2022.
Strategic Goals
This acquisition aligns with BioNTech’s strategy to enhance its capabilities in AI-driven drug discovery and the development of next-generation immunotherapies and vaccines. InstaDeep will function as a UK-based global subsidiary of BioNTech, continuing to serve its existing clients across various industries such as Technology, Transport & Logistics, Industrial, and Financial Services.
Workforce Expansion
The transaction brings approximately 290 highly skilled professionals into BioNTech’s workforce, including experts in AI, ML, bioengineering, data science, and software development. This addition is expected to bolster BioNTech’s efforts in addressing diseases with high unmet medical needs.
Financial Details
The total consideration for acquiring the remaining shares of InstaDeep, excluding those already owned by BioNTech, amounts to approximately €500 million. This includes cash, BioNTech shares, and performance-based future milestone payments.
